Sunovion nabs FDA's blessing for seizure drug; Boehringer eyes animal health buyout;

@FiercePharma:  Best-read special report this weekend: Top 10 Patent Losses for 2014. Report | Follow @FiercePharma

@CarlyHFierce:  Rare-disease co. ViroPharma finally snatched up after lots of speculation--Shire gets it for $4.2B. Release | Follow @CarlyHFierce

> Sunovion won FDA approval for its new seizure drug Aptiom (eslicarbazepine) on data showing it reduced the frequency of seizures compared with placebo. Report

> German drugmaker Boehringer Ingelheim is eyeing an expansion in animal health with an offer for the poultry vaccines and feed additives maker Lohmann, Reuters says. Report

> Alexion ($ALXN) said four new trials show its drug Soliris benefits patients with atypical hemolytic uremic syndrome. Report

> A federal appeals court blocked the Affordable Care Act's requirement that employers offer birth-control coverage in employee insurance. Report (sub. req.)

> USPLabs is recalling OxyElit Pro supplements that have been linked to an outbreak of liver illness. Report

> Indonesia's state-owned drugmaker Kimia Farma reportedly has canceled its plan to issue bonds. Report

Medical Device News

@FierceMedDev: Pfizer, marketing partner pay MA fine for ad overstating EpiPen's benefits. More | Follow @FierceMedDev

@MarkHFierce: Novartis is unloading its blood transfusion Dx unit for more than $1.6B PR. Article | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Chinese investors pursue groundbreaking med tech from Canada's MDI. Story | Follow @MichaelGFierce

> Topera rolls out next-gen heart imaging tech in wake of U.S., EU sign-offs. Story

> TB Dx maker Oxford Immunotec prices IPO shares. More

> FDA report: Intuitive's robots beneficial, but training still lacking. News

Biotech News

@FierceBiotech: Shire pays a steep premium to nab ViroPharma in $4.2B deal. More | Follow @FierceBiotech

@JohnCFierce: Just a few weeks ago Zalicus ($ZLCS) did a 6 for one reverse split to get its stock price back into compliance. Oh well. | Follow @JohnCFierce

@DamianFierce: Still-blazing IPO market takes Ultragenyx from "next year" to "right now." News | Follow @DamianFierce

@EmilyMFierce: Japanese Global Health Innovative Technology Fund awards $5.7M in grants for infectious disease vaccine work. Story | Follow @EmilyMFierce

> PhIII judgment day looms for GlaxoSmithKline's heart drug darapladib. Story

> Global biopharma hub strategy doomed Novartis' outlying R&D facility. Article

CRO News

> Cel-Sci demands $50M from inVentiv over alleged trial fraud. More

> Quintiles paid $146.5M for Novella. Article

> Capsugel bets $20M on Bend's commercial manufacturing. Story

> AMRI steers clear of FDA warning letter after years of fixes. Piece

> Covance partners up for biologics safety testing. Story

Biotech IT News

> Scientists increasingly receptive to life science vendors on social media. News

> Open-access genomics database causes hand-wringing in U.K. More

> Catalent creates web-based tool to ease drug delivery tech selection. Story

> BioDatomics pitches open-source, freemium bioinformatics package. Piece

> Advocacy groups crowdsourcing patient views on risk-benefit of drugs. News

And Finally... The iPhone game Plague Inc. has fans at the Centers for Disease Control and Prevention (CDC) for raising public awareness. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.